Pregnancy after Combined HMG-HCG Treatment in Amenorrheic Patients

Pasetto, N; Montanino, G

doi:10.1016/s0015-0282(16)36431-7

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attention was drawn by Borth, Lunenfeld & DeWatteville (1954) to the possibility of using post-menopausal extracts in the treatment of infertility and this has proved to be a convenient source of gonadotrophins for clinical use. The usage of HMG throughout the world has led to a considerable literature but extensive experience has been reported by Kase, Mroueh & Buxton (1968), Pasetto & Montanino (1967), Rabau et al (1967), Roland (1969) and Vande Wiele & Turksoy (1965). HMG is available as Pergonal in the U.K. and many other countries and the results to be discussed later relate to this material.…”

Section: Source Of Materialsmentioning

confidence: 99%

Clinical results with human gonadotrophins in anovulation, using two alternative dosage schemes

Butler¹

1972

Postgraduate Medical Journal

View full text Add to dashboard Cite

Section: Source Of Materialsmentioning

confidence: 99%

Clinical results with human gonadotrophins in anovulation, using two alternative dosage schemes

Butler¹

1972

Postgraduate Medical Journal

View full text Add to dashboard Cite

“…Although hMG revolutionized fertility treatment, adverse effects such as formation of lutein cysts and multiple pregnancies were reported (Pasetto and Montanino, 1967). The exact composition of hMG remained an area of debate; were FSH and LH one compound, or could they be separated?…”

mentioning

confidence: 99%

The Evolution of in Vitro Fertilization: Integration of Pharmacology, Technology, and Clinical Care

Feinberg

Bromer

Catherino

2005

J Pharmacol Exp Ther

View full text Add to dashboard Cite

For the couple having trouble achieving pregnancy, the options and opportunities for assistance have never been brighter. Options such as controlled ovarian hyperstimulation, in vitro fertilization, and intracytoplasmic sperm injection have been developed over the past five decades and provide hope for couples that previously would have been considered infertile. In vitro fertilization and intracytoplasmic sperm injection represent a coalescence of advances in physiology, endocrinology, pharmacology, technology, and clinical care. In vitro fertilization has assisted well over one million couples in their efforts to start or build a family, and the demand for such services continues to increase. The purpose of this manuscript is to review the pharmacological advances that made controlled ovarian hyperstimulation, and therefore in vitro fertilization and intracytoplasmic sperm injection, possible. We will discuss the early stages of gonadotropin use to stimulate ovarian production of multiple mature eggs, the advances in recombinant technology that allowed purified hormone for therapy, and the use of other hormones to regulate the menstrual cycle such that the likelihood of successful oocyte retrieval and embryo implantation is optimized. Finally, we will review current areas that require particular attention if we are to provide more opportunity for infertile couples.Controlled ovarian hyperstimulation (COH), in vitro fertilization (IVF), and intracytoplasmic sperm injection have become the standard of care for many couples with infertility. The combination of pharmacologic and surgical manipulation of the menstrual cycle is the key to improving pregnancy rates. The history and evolution of COH, IVF, and intracytoplasmic sperm injection has been rapidly developing and continues to change at an ever increasing pace (Fig. 1). As we learn more about the molecular basis of cellular communication and signaling, pharmacologic treatments with greater efficacy can be developed. Improvements in embryo culture techniques and embryo cryopreservation will similarly enhance outcomes. The purpose of this review is to summarize the history and development of the pharmacology that has made COH and IVF successful.In a typical menstrual cycle, there is the formation of a single dominant follicle, from which ovulation of a single oocyte occurs each month. For the fertile couple, this menstrual cycle has a 20% chance of resulting in a pregnancy; however, for infertile couples, the chance of pregnancy with one oocyte can be well under 5% per cycle. Over the past 50 years, pharmacologic agents have been developed to increase the likelihood of pregnancy by increasing the number of eggs released and available for fertilization.To clarify the obstacles to fertility that have been overcome as well as the challenges that remain, we will review the physiology of the menstrual cycle, major historical developments, and the therapeutic evolution and current use of medications used during controlled ovarian hyperstimulation and in vitro...

show abstract

Use of gonadotropins in infertile patients

Galliano

2017

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

Pregnancy after Combined HMG-HCG Treatment in Amenorrheic Patients

Cited by 5 publications

References 10 publications

Clinical results with human gonadotrophins in anovulation, using two alternative dosage schemes

Clinical results with human gonadotrophins in anovulation, using two alternative dosage schemes

The Evolution of in Vitro Fertilization: Integration of Pharmacology, Technology, and Clinical Care

Use of gonadotropins in infertile patients

Contact Info

Product

Resources

About